Potiga Whizzes Through Advisory Panel Review With Thorough Risk Management Plan

Despite urinary retention and a number of other concerning side effects, GlaxoSmithKline and Valeant's epilepsy drug ezogabine carries the day, based in part on a pledge to do a post-market observational safety study.